Acute Coronary Syndrome | Renal Denervation in Patients After Acute Coronary Syndrome

Acute Coronary Syndrome research study

What is the primary objective of this study?

This study is aimed to evaluate the effect of renal denervation to decreasing blood pressure and left ventricle remodeling progression in patients after acute coronary syndrome.

Who is eligible to participate?

Inclusion Criteria: - acute Q negative myocardium infarction (during first 14 days) - non stable angina - significant stenosis - BP > 140/90 torr. during more than 1 year Exclusion Criteria: - absence of arterial hypertension - Thrombolysis during previous 24 hours - indications for CABG

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Acute Coronary Syndrome

Arterial Hypertension

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Procedure:Renal denervationThe treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.

Drug:MetoprololBeta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.

Drug:LisinoprilACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

PCI+Renal denervation

PCI alone

Study Status

Unknown status

Start Date: June 2013

Completed Date: June 2016

Phase: Phase 2

Type: Interventional


Primary Outcome: cardiovascular death

Secondary Outcome: blood pressure changes

Study sponsors, principal investigator, and references

Principal Investigator: Evgeny Pokushalov, MD, PhD

Lead Sponsor: Meshalkin Research Institute of Pathology of Circulation


More information:

Discuss Lisinopril